Other languages Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
2.89 ^USD	-3.99%		-9.12%	-4.93%

May. 15	Kodiak Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 14	Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kodiak Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy	May. 13
Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate Platform	May. 02
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 28
Sector Update: Health Care	Mar. 28
Top Midday Decliners	Mar. 28
Kodiak Sciences Shares Tumble After Wider-Than-Expected Q4 Loss	Mar. 28
Kodiak Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Kodiak Sciences Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28
Ausblick Lonza: Jahresumsatz von 6,5 Milliarden Franken erwartet	Jan. 25
Kodiak Sciences' Q3 Loss Narrows	Nov. 14
Kodiak Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Sector Update: Health Care Stocks Gain Late Afternoon	Nov. 06
Sector Update: Health Care	Nov. 06
Kodiak Sciences Share Fall; Company to Resume Tarcocimab Tedromer Eye Drug Development Program	Nov. 06
MIDDAY BRIEFING - Unternehmen und Märkte	Nov. 06
MARKT USA/Wall Street dürfte Gewinnserie fortsetzen	Nov. 06
Kodiak Sciences Inc. Announces Phase 3 Glow Superiority Study Evaluating Tarcocimab Tedromer 5 Mg in Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy	Nov. 06
Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting	Nov. 01
Lonza setzt sich nach dem Ende der Pandemie neue Ziele	23-10-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Other languages

Filters